Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.150
+0.030 (2.68%)
Mar 11, 2025, 4:00 PM EST - Market closed
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 49 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
49
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,653
Profits / Employee
-$835,000
Market Cap
35.88M
Employees Chart
ATNM News
- 16 hours ago - Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML - PRNewsWire
- 3 months ago - My Top 2 Stock Picks For A 2025 Rebound - Seeking Alpha
- 4 months ago - SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player - PRNewsWire
- 4 months ago - Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024 - PRNewsWire
- 4 months ago - Actinium Pharmaceuticals, Inc. Is Being Investigated For Securities Related Infractions And Shareholders With Losses Are Urged To Contact The Schall Law Firm - Accesswire
- 4 months ago - Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors - PRNewsWire
- 4 months ago - The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud - Accesswire
- 4 months ago - Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm - Accesswire